{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:45:45Z","timestamp":1790084745024,"version":"4.0.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To analyse utilization and discontinuation of secondary preventive medications after acute myocardial infarction (MI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>In separate analyses for each drug [statins, beta-blockers, aspirin, and renin-angiotensin-aldosterone system (RAAS) inhibitors], patients with a first-time MI (2006\u20132021) registered in the nationwide Swedish MI register SWEDEHEART, surviving &amp;gt;30 days, and discharged with a new prescription of the drug were included. Based on filled prescriptions, treatment initiation, discontinuation (defined as \u226590-day period of non-treatment after the end of previous prescriptions), reinitiation (restarting treatment after discontinuation), and the proportion of patients with ongoing treatment at various time points after the MI were assessed. The analyses included 159 155 patients: 122 288 patients discharged with a statin, 79 968 with a RAAS inhibitor, 105 095 with a beta-blocker, and 127 463 with aspirin: 95%\u201397% of the patients filled their first prescription for the drug. Treatment discontinuation ranged from 12% to 14% at 1 year, 27%\u201337% at 5 years, and 36%\u201351% at 12 years across drugs. Among those who discontinued treatment, the proportion who reinitiated treatment was 28%\u201346% at 1 year, 42%\u201362% at 5 years, and 47%\u201367% at 12 years after discontinuation across drugs. The proportion of patients who were alive with ongoing treatment (regardless of previous discontinuation\/reinitiation episodes) was 91%\u201392% at 1 year, 79%\u201382% at 5 years, and 74%\u201379% at 12 years after the index MI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Discontinuation of secondary preventive medications was common, but so was reinitiation. Thus, the proportion of patients with ongoing treatment was 91%\u201392% at 1 year and 74%\u201379% at 12 years after the MI. This study, which did not assess reasons for drug discontinuation, indicates that long-term utilization of secondary preventive medication after MI may not be as low as previously thought.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf079","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:18:17Z","timestamp":1761830297000},"page":"15-24","source":"Crossref","is-referenced-by-count":5,"title":["Utilization and discontinuation of secondary prevention pharmacotherapy after myocardial infarction: a nationwide cohort study"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0196-4894","authenticated-orcid":false,"given":"Ali","family":"Yari","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0501-9678","authenticated-orcid":false,"given":"Carl-Emil","family":"Lim","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet , 171 76 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3221-0144","authenticated-orcid":false,"given":"Emil","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9614-0486","authenticated-orcid":false,"given":"Pia","family":"Lundman","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1917-5885","authenticated-orcid":false,"given":"Jessica","family":"Schubert","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University , 751 85 Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1695-379X","authenticated-orcid":false,"given":"Tomas","family":"Jernberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet , 182 88 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-8743","authenticated-orcid":false,"given":"Peter","family":"Ueda","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine, Solna, Karolinska Institutet , 171 76 Stockholm ,","place":["Sweden"]},{"name":"Centre for Diabetes, Academic Specialist Centre , 113 65 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026020209255767300_pvaf079-B1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"2026020209255767300_pvaf079-B2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1161\/CIRCULATIONAHA.111.041160","article-title":"American College of Cardiology\/American Heart Association\/European Society of Cardiology\/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38)","volume":"125","author":"Bonaca","year":"2012","journal-title":"Circulation"},{"key":"2026020209255767300_pvaf079-B3","doi-asserted-by":"crossref","first-page":"e014907","DOI":"10.1161\/JAHA.119.014907","article-title":"Association between subsequent hospitalizations and recurrent acute myocardial infarction within 1 year after acute myocardial infarction","volume":"9","author":"Wang","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026020209255767300_pvaf079-B4","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s00125-010-1783-z","article-title":"Changes in short- and long-term cardiovascular risk of incident diabetes and incident myocardial infarction\u2013a nationwide study","volume":"53","author":"Norgaard","year":"2010","journal-title":"Diabetologia"},{"key":"2026020209255767300_pvaf079-B5","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026020209255767300_pvaf079-B6","first-page":"e344","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"key":"2026020209255767300_pvaf079-B7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2012.11.018","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O'Gara","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026020209255767300_pvaf079-B8","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"82","author":"Writing Committee Members","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026020209255767300_pvaf079-B9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00228-013-1614-5","article-title":"Use of the recommended drug combination for secondary prevention after a first occurrence of acute coronary syndrome in France","volume":"70","author":"Bezin","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"2026020209255767300_pvaf079-B10","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamacardio.2017.0911","article-title":"Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries","volume":"2","author":"Colantonio","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026020209255767300_pvaf079-B11","doi-asserted-by":"crossref","first-page":"961.e7","DOI":"10.1016\/j.amjmed.2008.12.021","article-title":"Long-term medication adherence after myocardial infarction: experience of a community","volume":"122","author":"Shah","year":"2009","journal-title":"Am J Med"},{"key":"2026020209255767300_pvaf079-B12","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/eurjpc\/zwae194","article-title":"Two-year prognosis and cardiovascular disease prevention after acute coronary syndrome: the role of cardiac rehabilitation-a French nationwide study","volume":"31","author":"Blacher","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026020209255767300_pvaf079-B13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.amjcard.2014.08.010","article-title":"Persistence of evidence-based medication use after discharge from academic versus nonacademic hospitals among patients with non-ST-segment elevation myocardial infarction","volume":"114","author":"Rymer","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026020209255767300_pvaf079-B14","first-page":"800","article-title":"Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction","volume":"101","author":"Shore","year":"2015","journal-title":"Heart (British Cardiac Society)"},{"key":"2026020209255767300_pvaf079-B15","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/eurheartj\/ehi705","article-title":"Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction","volume":"27","author":"Gislason","year":"2006","journal-title":"Eur Heart J"},{"key":"2026020209255767300_pvaf079-B16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12872-016-0283-6","article-title":"Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction","volume":"16","author":"Halvorsen","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"key":"2026020209255767300_pvaf079-B17","doi-asserted-by":"crossref","first-page":"e003626","DOI":"10.1161\/CIRCOUTCOMES.117.003626","article-title":"Statin discontinuation, reinitiation, and persistence patterns among medicare beneficiaries after myocardial infarction: a cohort study","volume":"10","author":"Booth","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026020209255767300_pvaf079-B18","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.166.17.1842","article-title":"Impact of medication therapy discontinuation on mortality after myocardial infarction","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"key":"2026020209255767300_pvaf079-B19","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.acvd.2008.04.005","article-title":"Persistence of combination of evidence-based medical therapy in patients with acute coronary syndromes","volume":"101","author":"Amar","year":"2008","journal-title":"Arch Cardiovasc Dis"},{"key":"2026020209255767300_pvaf079-B20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2015.03.019","article-title":"Persistence with secondary prevention medications after acute myocardial infarction: insights from the TRANSLATE-ACS study","volume":"170","author":"Mathews","year":"2015","journal-title":"Am Heart J"},{"key":"2026020209255767300_pvaf079-B21","first-page":"1617","article-title":"The Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies (SWEDEHEART)","volume":"96","author":"Jernberg","year":"2010","journal-title":"Heart (British Cardiac Society)"},{"key":"2026020209255767300_pvaf079-B22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s10654-009-9350-y","article-title":"The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research","volume":"24","author":"Ludvigsson","year":"2009","journal-title":"Eur J Epidemiol"},{"key":"2026020209255767300_pvaf079-B23","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/pds.1294","article-title":"The new Swedish Prescribed Drug Register\u2013opportunities for pharmacoepidemiological research and experience from the first six months","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026020209255767300_pvaf079-B24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2026020209255767300_pvaf079-B25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M18-0543","article-title":"ESPACOMP Medication Adherence Reporting Guideline (EMERGE)","volume":"169","author":"De Geest","year":"2018","journal-title":"Ann Intern Med"},{"key":"2026020209255767300_pvaf079-B26","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/MLR.0b013e31829b1d2a","article-title":"Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases","volume":"51","author":"Raebel","year":"2013","journal-title":"Med Care"},{"key":"2026020209255767300_pvaf079-B27","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/pds.4582","article-title":"Using the \u201cproportion of patients covered\u201d and the Kaplan\u2013Meier survival analysis to describe treatment persistence","volume":"27","author":"Rasmussen","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026020209255767300_pvaf079-B28","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"key":"2026020209255767300_pvaf079-B29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jclinepi.2005.05.005","article-title":"Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation","volume":"59","author":"Van Wijk","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"2026020209255767300_pvaf079-B30","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12944-019-1099-z","article-title":"Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis","volume":"18","author":"Toth","year":"2019","journal-title":"Lipids Health Dis"},{"key":"2026020209255767300_pvaf079-B31","doi-asserted-by":"crossref","first-page":"oeac070","DOI":"10.1093\/ehjopen\/oeac070","article-title":"Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs","volume":"2","author":"Engebretsen","year":"2022","journal-title":"Eur Heart J Open"},{"key":"2026020209255767300_pvaf079-B32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/joim.12303","article-title":"Review of 103 Swedish Healthcare Quality Registries","volume":"277","author":"Emilsson","year":"2015","journal-title":"J Intern Med"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf079\/65138460\/pvaf079.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/1\/15\/65138460\/pvaf079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/1\/15\/65138460\/pvaf079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:36:33Z","timestamp":1770042993000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/1\/15\/8313700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf079","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,11,4]]}}}